Viva Biotech Holdings (1873.HK)
| Previous close | 0.560 |
| Open | 0.560 |
| Bid | 0.560 x N/A |
| Ask | 0.580 x N/A |
| Day's range | 0.550 - 0.600 |
| 52-week range | 0.410 - 2.000 |
| Volume | |
| Avg. volume | 4,920,202 |
| Market cap | 1.199B |
| Beta (5Y monthly) | 1.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.150 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 16 June 2021 |
| 1y target est | 7.97 |
PR NewswireViva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
On March 28, 2024, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue during the Reporting Period achieved RMB2,155.6 million; and our gross profit amounted to RMB738.5 million. In 2023, the Group's net loss amounted to RMB99.8 million, a significant improvement from a loss of RMB504.2 million for the corresponding period of last year. Adjusted non-IFRS net loss improved from RMB133.9 million for the corresponding pe
- PR Newswire
Viva Biotech Secures Approximately US$ 210 Million Funding
On November 20, 2023, Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US$210 million and bringing in the strategic investors, Temasek, Highlight Capital (HLC), and True Light. Following this transaction, the Viva Biotech Holdings group obtained financing of nearly US$150 million through the transfer of approximately 24.21% equity in its CRO business entity, Viva Biotech (Shanghai) Limited. Before, the publicly listed company at the group
- PR Newswire
Viva Biotech (1873.HK) Announces 2023 Interim Results：Solid Growth in Main Business, Significant Rebound in Profitability
On August 29, 2023, Viva Biotech Holdings Group ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that during the period ended June 30, 2023 (the "Reporting Period"), the revenue of the Group during the Reporting Period increased by approximately 3.0% from RMB1,108.7 million for the corresponding period of last year to RMB1,142.2 million; and the gross profit increased by approximately 17.7% from RMB345.0 million for the corresponding period of last year to RMB406.0 m
